Update
$Chemomab Therapeutics (CMMB.US)$ Chemomab Therapeutics Announces Positive Phase 2 Trial Results: Cm-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients With Primary Sclerosing Cholangitis
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
